Corporate Profile

Affymax, Inc. is a biopharmaceutical company developing novel peptide-based drug candidates to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, Hematide™ is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure and is in Phase 2 clinical trials for the treatment of anemia in cancer patients.

Webcasts

May 21, 2008
2008 Citi Investment Research Global Health Care Conference

Recent Press Releases

Jul 9, 2008
Affymax Completes Enrollment in PEARL 1, the First of Four Phase 3 Clinical Trials of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients

Jun 30, 2008
Affymax Initiates Clinical Trial of Hematide(TM) to Evaluate Correction of Anemia in Chronic Renal Failure Patients on Dialysis